title: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
authors.affiliation: Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. rustin@mtvern.co.uk
authors.forename: Gordon J S
authors.initials: GJ
authors.lastname: Rustin
authors.forename: Robert C
authors.initials: RC
authors.lastname: Bast
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: J Carl
authors.initials: JC
authors.lastname: Barrett
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Carter
authors.forename: Perry D
authors.initials: PD
authors.lastname: Nisen
authors.forename: Caroline C
authors.initials: CC
authors.lastname: Sigman
authors.forename: David R
authors.initials: DR
authors.lastname: Parkinson
authors.forename: Raymond W
authors.initials: RW
authors.lastname: Ruddon
mesh_terms: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen / Q000096:biosynthesis*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D015195:Drug Design; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D011379:Prognosis; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen